Joe Illingworth

Company: DJS Antibodies

Job title: Chief Scientific Officer & Co-Founder

Seminars:

Panel Discussion: Which Modality to Choose? Debating the Implementation of Biologics vs Small Molecules 4:45 pm

With only 3 FDA approved antibodies and roughly 20 in development, what are the hurdles to showing efficacy in antibody drug development for GPCRs Will antibodies replace small molecules in the GPCR space? Are there indications where an antibody may fair better or equal to small molecules (oncology space?)Read more

day: Day One

Showcasing Discovery and Validation of a Known GPCR Target Using an Antibody [case study] 1:45 pm

Highlighting the existing challenges with antibody modulated GPCR targeting Relaying a novel approach used to target with a large molecule Spearheading early clinical developmentRead more

day: Day One